San Antonio Breast Cancer Symposium | Conference

Positive CTC Findings Linked to High Recurrence Risk in HR+ Breast Cancer

December 9th 2017

Detection of positive circulating tumor cells in the blood 5 years after a breast cancer diagnosis was associated with an increased risk for late recurrence in women with HR–positive, HER2-negative breast cancer

Pembrolizumab/Eribulin Efficacy Maintained for TNBC in Larger Dataset

December 9th 2017

Treatment with the combination of pembrolizumab (Keytruda) and eribulin (Halaven) demonstrated a 26.4% objective response rate for patients with metastatic triple-negative breast cancer.

Dr. Burstein Discusses Key Updates from the SOFT Trial

December 9th 2017

Harold Burstein, MD, PhD, medical oncologist, Dana-Farber Cancer Institute discusses some key findings from the follow-up data from the SOFT trial.

Even Moderate Weight Loss Helps Prevent Breast Cancer in Postmenopausal Women

December 9th 2017

Losing even some extra weight significantly reduces the risk of breast cancer for postmenopausal women, expert says.

Neoadjuvant Abemaciclib Active in Early Breast Cancer

December 8th 2017

Neoadjuvant treatment with abemaciclib (Verzenio) plus anastrozole induced complete cell cycle arrest as measured by Ki67 for 67.8% of patients with HR-positive/HER2-negative early-stage breast cancer.

CDK4/6 Improved PFS in Older Women with HR+ Metastatic Breast Cancer

December 8th 2017

Older women with HR–positive breast cancer treated with a CDK4/6 inhibitor may derive a progression-free survival benefit similar to that seen in their younger counterparts

Talazoparib Improves PFS in BRCA-Positive Breast Cancer

December 8th 2017

The PARP inhibitor talazoparib reduced the risk of disease progression or death by 46% versus chemotherapy in patients with BRCA-positive advanced breast cancer.

Dr. Hershman Discusses Acupuncture for Arthralgia

December 8th 2017

Dawn Hershman, MD, MS, professor of Medicine and Epidemiology, Columbia University Medical Center, discusses the use of acupuncture to treat joint pain caused by aromatase inhibitors in patients with breast cancer.

Nab-Paclitaxel Improves DFS Over the Long Term in Early Breast Cancer

December 8th 2017

Substituting nab-paclitaxel (Abraxane) for solvent-based paclitaxel as neoadjuvant chemotherapy improved disease-free survival in patients with high-risk early breast cancer.

Dr. Domchek Discusses Unanswered Questions from the MEDIOLA Trial

December 8th 2017

Susan Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses some questions that remain after the recent phase II MEDIOLA trial.

Dr. Moore Discusses Ovarian Preservation in Breast Cancer

December 8th 2017

Halle Moore, MD, medical oncologist, the Cleveland Clinic, discusses the use of GnRH agonists to preserve ovarian function and fertility in women with breast cancer.

Nab-Paclitaxel Shows Greatest Utility for TNBC

December 8th 2017

Treatment with nab-paclitaxel showed promising improvements in overall survival and progression-free survival compared with standard paclitaxel for patients with metastatic triple-negative breast cancer.

No Difference in Overall Survival with Shorter Extended AI Therapy

December 7th 2017

Investigators with the Austria Breast and Colorectal Cancer Study Group announced today that years can safely be shaved off anastrozole (Arimidex) treatment without affecting disease-free survival postmenopausal HR-positive breast cancer.

Acupuncture Reduces AI-Associated Joint Pain in Women with Breast Cancer

December 7th 2017

A mix of traditional and customized acupuncture techniques proved effective in reducing pain and stiffness associated with aromatase inhibitor (AI) therapy in women with early-stage breast cancer.

1-Year of Adjuvant Trastuzumab Remains Standard in HER2+ Breast Cancer

December 7th 2017

The phase III SOLD trial failed to demonstrate that DFS with 9 weeks of adjuvant trastuzumab was noninferior to the standard 12 months when the 2 regimens were combined with chemotherapy in women with early stage HER2-positive breast cancer.

GnRHa May Protect Ovarian Function, Preserve Fertility in Premenopausal Women With Early-Stage Breast Cancer

December 7th 2017

Results from a meta-analysis of data collected from 837 premenopausal women undergoing chemotherapy for early-stage breast cancer suggest that gonadotropin-releasing hormone analog may preserve fertility and have a protective ovarian function.

Dr. Coombes on Intriguing Results With Celecoxib in Breast Cancer

December 7th 2017

Charles Coombes, MD, professor of medical oncology, Imperial College London, discusses surprising results from a recent study examining celecoxib’s impact on breast cancer progression and relapse.

Dr. Rimawi Discusses the Clinical Need for Immunotherapy in HER2-Positive Breast Cancer

December 7th 2017

Mothaffar F. Rimawi, MD, associate professor and director of clinical research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses the clinical need for immunotherapy regimens for patients with HER2-positive breast cancer.

Ribociclib Improves PFS by 10.8 Months in HR+/HER2- Premenopausal Breast Cancer

December 7th 2017

Newly released results from the MONALEESA-7 trial showed that adding ribociclib to standard endocrine therapy with temporary ovarian suppression significantly improved progression-free survival as a first-line treatment for pre- and perimenopausal women with advanced HR-positive/HER2-negative breast cancer.

Dr. Nangia Discusses the Logistics of Implementing a Scalp Cooling System

December 7th 2017

Julie R. Nangia, MD, assistant professor of medicine, Baylor College of Medicine, discusses some logistical factors that oncologists and health care providers should know regarding implementing a scalp cooling system.